<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In Germany, the only available interleukin-1beta (IL-1beta) blocking agent is anakinra (ANR) (as of August 2009) which is given subcutaneously at a dosage of 100 mg/day (adults) and 1-2 mg/kg body weight/day (maximum 100 mg/day) (children), respectively </plain></SENT>
<SENT sid="1" pm="."><plain>Based on published data and clinical experience the German Society of Rheumatology (Deutsche Gesellschaft f√ºr Rheumatologie) recommends the following indications for ANR: (1) <z:hpo ids='HP_0001370'>Rheumatoid arthritis</z:hpo>, if treatment with two DMARDs (one of the two being <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, MTX) for at least 6 months has failed </plain></SENT>
<SENT sid="2" pm="."><plain>(2) <z:hpo ids='HP_0003581'>Adult-onset</z:hpo> and <z:hpo ids='HP_0003621'>juvenile-onset</z:hpo> <z:e sem="disease" ids="C0087031" disease_type="Disease or Syndrome" abbrv="">Still's disease</z:e> (systemic juvenile idiopathic <z:hpo ids='HP_0001369'>arthritis</z:hpo>) in the case of insufficient response to <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> or inadequate long-term dosage, as well as failure of a conventional DMARD, usually MTX </plain></SENT>
<SENT sid="3" pm="."><plain>For both indications the treatment should be supervised and documented by a rheumatologist or paediatric rheumatologist </plain></SENT>
<SENT sid="4" pm="."><plain>Cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndromes</z:e> (CAPS) are recommended as an additional treatment option for IL-1 blocking therapy </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy of the fusion protein rilonacept (RIC) and the monoclonal antibody canakinumab in the treatment of CAPS has been proven by randomized, placebo-controlled trials </plain></SENT>
<SENT sid="6" pm="."><plain>In the US, RIL was recently approved by the FDA for the treatment of CAPS under the "Orphan Drug Status" </plain></SENT>
</text></document>